Efficacy and safety of oral conivaptan: a V1A/V2 vasopressin receptor antagonist, assessed in a randomized, placebo-controlled trial in patients with euvolemic or hypervolemic hyponatremia

The Journal of Clinical Endocrinology and Metabolism
J K GhaliNeila Smith

Abstract

Hyponatremia [serum sodium concentration ([Na(+)]), <135 mEq/liter] is the most common fluid and electrolyte abnormality among hospitalized patients. It is frequently caused by the inappropriate release of arginine vasopressin. The objective of this study was to evaluate the efficacy and safety of oral conivaptan, a vasopressin V(1A)/V(2) receptor antagonist, in patients with euvolemic or hypervolemic hyponatremia. The study design was a 5-d placebo-controlled, randomized, double-blind study. The study was performed at a hospital. Oral conivaptan (40 or 80 mg/d) or placebo was given in two divided doses. Seventy-four patients (average baseline serum [Na(+)], 115 to <130 mEq/liter) were studied. The main outcome measure was the change from baseline in serum [Na(+)] area under the curve. The least-squares mean change from baseline in the serum [Na(+)] area under the curve with conivaptan (40 and 80 mg/d) was 2.0-fold (P = 0.03) and 2.5-fold (P < 0.001) greater, respectively, than that with placebo. The median time to achieve a confirmed increase in serum [Na(+)] of 4 mEq/liter or more from baseline was 71.7 h for placebo, 27.5 h for 40 mg/d conivaptan (P = 0.044), and 12.1 h for 80 mg/d conivaptan (P = 0.002). The mean total time...Continue Reading

Citations

Feb 24, 2012·Pediatric Nephrology : Journal of the International Pediatric Nephrology Association·Michael L Moritz
Aug 19, 2007·Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer·Harry Raftopoulos
Sep 4, 2008·Current Heart Failure Reports·Dimitrios FarmakisMihai Gheorghiade
Oct 30, 2008·Current Neurology and Neuroscience Reports·Joshua M Levine
Feb 13, 2009·Current Treatment Options in Neurology·Joshua M Levine
Jan 6, 2009·Neurocritical Care·Theresa MurphyMichael Diringer
Feb 28, 2009·Canadian Journal of Anaesthesia = Journal Canadien D'anesthésie·Sean M BagshawRobert C McDermid
Nov 30, 2011·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Brian P WalcottJ Marc Simard
Sep 18, 2013·Clinical Neurology and Neurosurgery·Jonathan D BreshearsLewis S Blevins
Jan 26, 2007·Nature Clinical Practice. Nephrology·Sheldon ChenDaniel Batlle
Feb 2, 2011·Nature Reviews. Endocrinology·Gary L Robertson
May 18, 2007·The New England Journal of Medicine·David H Ellison, Tomas Berl
Feb 29, 2008·Harvard Review of Psychiatry·Arthur J Siegel
Nov 3, 2009·NDT Plus·Robert ZietseEwout J Hoorn
Oct 12, 2010·Cardiology in Review·Nadia Ferguson-Myrthil
Sep 23, 2009·International Journal of Clinical Practice·P Reddy, A D Mooradian
Jun 17, 2011·Nephron. Clinical Practice·Pasquale EspositoAntonio Dal Canton
Nov 14, 2012·Therapeutic Advances in Endocrinology and Metabolism·Peter Gross
Oct 16, 2010·Critical Care : the Official Journal of the Critical Care Forum·Guy DecauxAlain Soupart
Oct 17, 2009·Neurosurgery·Maryam Rahman, William A Friedman
Feb 27, 2010·Journal of the American Society of Nephrology : JASN·Tomas BerlUNKNOWN SALTWATER Investigators
Aug 10, 2010·Core Evidence·Melissa Li-Ng, Joseph G Verbalis
Jan 8, 2010·Drug Design, Development and Therapy·Jalal K GhaliHammam D Zmily
Jan 1, 2010·International Journal of Nephrology and Renovascular Disease·Savina NodariJun R Chiong
Jul 9, 2010·Future Cardiology·Ewout J Hoorn, Robert Zietse
Feb 27, 2014·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Goce SpasovskiUNKNOWN Hyponatraemia Guideline Development Group
Oct 12, 2010·Journal of Endocrinological Investigation·A PeriP Menè
Feb 27, 2014·European Journal of Endocrinology·Goce SpasovskiUNKNOWN Hyponatraemia Guideline Development Group
Jan 29, 2008·Current Heart Failure Reports·Filippo BrandimarteMihai Gheorghiade
Mar 13, 2008·Der Internist·R Lemmens-Gruber, M Kamyar
Sep 2, 2008·Heart Failure Reviews·Dimitrios FarmakisMihai Gheorghiade
Sep 9, 2008·Heart Failure Reviews·Steven R Goldsmith
Sep 15, 2010·Heart Failure Reviews·Luca BettariChristopher M O'Connor
Nov 1, 2011·Clinical and Experimental Nephrology·Yoko FujiwaraTaka-Aki Koshimizu
Nov 23, 2011·Expert Review of Cardiovascular Therapy·Luna GarganiMihai Gheorghiade
Feb 2, 2012·Expert Review of Cardiovascular Therapy·Doron Aronson
Oct 10, 2007·Expert Opinion on Investigational Drugs·Lisa C Costello-BoerrigterJohn C Burnett
Oct 25, 2007·Expert Opinion on Pharmacotherapy·Sabiha M HussainRichard J Marcus
Feb 16, 2011·Expert Opinion on Investigational Drugs·Elwaleed A Elhassan, Robert W Schrier
Aug 31, 2012·Kidney International·William T AbrahamUNKNOWN HARMONY Study Group
Oct 9, 2007·Cardiovascular Drug Reviews·Farhan AliJalal K Ghali
Feb 11, 2015·Journal of the American College of Cardiology·Frederik H VerbruggeWilfried Mullens
Jul 10, 2003·American Heart Journal·Craig R LeeKirkwood F Adams
Aug 7, 2007·The American Journal of Medicine·Yeong-Hau H Lien, Joseph I Shapiro
Jun 4, 2008·Seminars in Nephrology·Sumit Kumar, Tomas Berl

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.